CHMA:NSD-Chiasma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.19

Change

0.00 (0.00)%

Market Cap

USD 0.24B

Volume

0.49M

Average Target Price

USD 13.50 (+222.20%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD87.87B 146.68 115.30
BNTX BioNTech SE

N/A

USD57.61B -99,999.99 35.63
REGN Regeneron Pharmaceuticals, Inc

N/A

USD55.99B 14.96 11.72
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD49.97B 18.40 14.51
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.15B 58.96 42.44
BGNE BeiGene, Ltd

N/A

USD32.98B N/A N/A
SGEN Seagen Inc

N/A

USD28.42B 43.69 39.29
GMAB Genmab A/S

N/A

USD28.21B 26.59 3.61
RPRX Royalty Pharma plc

N/A

USD27.26B 22.60 16.58
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CHMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.68% 46% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.68% 46% F 23% F
Trailing 12 Months  
Capital Gain -31.54% 21% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.54% 21% F 7% F
Trailing 5 Years  
Capital Gain 63.04% 63% D 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.04% 62% D- 50% F
Average Annual (5 Year Horizon)  
Capital Gain 44.34% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.34% 73% C 83% B
Risk Return Profile  
Volatility (Standard Deviation) 108.34% 25% F 14% F
Risk Adjusted Return 40.92% 66% D 60% D-
Market Capitalization 0.24B 38% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.85 51% F 40% F
Price / Cash Flow Ratio -3.22 21% F 63% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -133.81% 16% F 7% F
Return on Invested Capital -78.56% 26% F 10% F
Return on Assets -37.05% 25% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.46 91% A- 85% B
Short Percent 7.56% 44% F 27% F
Beta 1.26 56% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector